drugset
drugset / Trial / NCT04771143

Study to Assess Safety, Tolerability, and Interactions of Cocaine and Oral AFQ056

NCT04771143 ↗

Phase 1 Withdrawn Novartis Pharmaceuticals National Institute on Drug Abuse (NIDA) · collab
RandomizedParallel-groupDouble-blindOther

Summary

This is a study to assess safety, tolerability and interactions of AFQ056 and cocaine in patients with cocaine use disorder.

Timeline

Start
2021-07-21
Primary completion
2022-01-03
Completion
2022-01-03

Outcome

Outcome not reported

Stopped (Enrollment): “study terminated/withdrawn before FPFV (no patients enrolled)”

Drugs

EvaluationDrugModalityDoseRoute
Subject Mavoglurant Small molecule 200 mg Oral

Indications

substance-related disorder